How does a urinary tract infection lead to secondary pseudohypoaldosteronism, and how common is this condition in infants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Secondary Pseudohypoaldosteronism in Infants with UTI

Secondary pseudohypoaldosteronism (S-PHA) is a life-threatening but transient condition that occurs in approximately 90% of cases when infants under 6 months with urinary tract infections (UTI) and/or congenital urinary tract malformations develop renal tubular resistance to aldosterone, resulting in severe hyponatremia, hyperkalemia, and metabolic acidosis.

Mechanism of UTI-Induced Pseudohypoaldosteronism

The pathophysiology involves renal tubular resistance to aldosterone triggered by multiple factors 1, 2:

  • Increased intrarenal pressure from infection and/or obstruction damages tubular function
  • Inflammatory mediators from UTI directly impair aldosterone receptor sensitivity in the distal tubules
  • Tubular immaturity in infants under 6 months makes them particularly vulnerable to aldosterone resistance
  • The combination creates a functional blockade where despite markedly elevated plasma renin and aldosterone levels, the kidneys cannot retain sodium or excrete potassium

This differs fundamentally from primary pseudohypoaldosteronism (genetic defect) or congenital adrenal hyperplasia (inadequate aldosterone production) - in S-PHA, the hormones are present in excess but the tubules cannot respond to them.

Prevalence and Risk Factors in Infants

S-PHA is uncommon but clinically significant when it occurs 1, 3:

Age Distribution

  • 92.2% of cases occur in infants younger than 6 months 1
  • Peak incidence in the first 3 months of life
  • Rare after 1 year of age

Gender and Associated Conditions

  • 81.9% occur in males 1, likely due to higher rates of obstructive uropathy (posterior urethral valves)
  • 90.5% have concurrent UTI 1
  • 50.9% have bilateral urinary tract malformations or solitary kidney 1

Specific Risk Profile

The highest-risk infant is:

  • Male, under 3 months old
  • Has obstructive uropathy (posterior urethral valves, vesicoureteral reflux grades III-V, hydronephrosis)
  • Presents with acute pyelonephritis
  • May have bilateral involvement or solitary kidney

Without UTI, S-PHA occurs almost exclusively with bilateral malformations 1, suggesting infection is the primary trigger in unilateral disease.

Clinical Recognition

Presentation

Infants present with nonspecific symptoms that mimic other serious conditions 4, 5:

  • Failure to thrive, poor weight gain
  • Vomiting and dehydration
  • Lethargy or irritability
  • May progress to shock and respiratory distress requiring intensive care

Laboratory Hallmarks

  • Severe hyponatremia (often <120 mmol/L)
  • Hyperkalemia (typically >6.0 mmol/L)
  • Metabolic acidosis with normal anion gap
  • Markedly elevated plasma renin activity and aldosterone (distinguishes from adrenal insufficiency)
  • Positive urine culture (usually E. coli or Klebsiella)

Critical Pitfall

The presentation mimics salt-losing congenital adrenal hyperplasia, which is the most important differential diagnosis 2, 5. Key distinguishing features:

  • S-PHA: High aldosterone and renin (resistance)
  • CAH: Low/normal aldosterone, high 17-hydroxyprogesterone (deficiency)
  • S-PHA: UTI and/or uropathy on imaging
  • CAH: Normal urinary tract, ambiguous genitalia in females

Management Approach

Treatment is primarily supportive, targeting the underlying infection and electrolyte correction 1, 4, 3:

Acute Phase

  1. Aggressive IV fluid resuscitation with normal saline
  2. Sodium supplementation (IV initially, then oral sodium chloride)
  3. Potassium correction (insulin/glucose, calcium gluconate for cardiac protection if severe)
  4. Sodium bicarbonate for metabolic acidosis
  5. Antibiotic therapy for documented UTI (culture-directed)

Resolution Timeline

  • 76.5% resolve with medical treatment alone 1
  • Electrolyte abnormalities typically normalize within days to weeks after UTI treatment
  • Surgical correction of underlying uropathy accelerates resolution and prevents recurrence

Surgical Considerations

Early surgical intervention for obstructive uropathy may prevent UTI recurrence and S-PHA episodes 1, 6. In cases requiring immediate surgery (severe obstruction), electrolyte imbalance often resolves post-operatively.

Recurrence Risk

S-PHA can recur with subsequent UTI episodes in infants under 3 months 6, particularly in those with uncorrected obstructive uropathy. This emphasizes the importance of:

  • Prophylactic antibiotics until surgical correction
  • Close monitoring of electrolytes during any febrile illness
  • Expedited surgical correction when feasible

Screening Recommendations

Check serum electrolytes in all infants under 6 months with 1, 3:

  • UTI (especially pyelonephritis)
  • Known urinary tract malformations presenting for surgery
  • Failure to thrive with dehydration
  • Any combination of the above

Obtain renal ultrasound in any infant with electrolyte disturbances to exclude obstructive uropathy 7, 3, as this may be the presenting sign of previously undiagnosed CAKUT.

The condition is transient and fully reversible with appropriate treatment, but delayed recognition can result in life-threatening complications including shock, cardiac arrhythmias, and acute kidney injury 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.